Melatonin Glenmark

Melatonin, the active ingredient in Melatonin Glenmark, is a melatonin receptor agonist presented as an oral dosage form for oral use. It helps regulate the sleep‑wake cycle and is used to manage sleep disorders in adults and children. The product is manufactured under EU standards and is intended for short‑term use to improve sleep onset and quality.

GNH USA supplies Melatonin Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Melatonin Glenmark acts on the melatonin receptor pathway to address disorders of the sleep‑wake cycle.

- Insomnia: helps reduce time to fall asleep and improve sleep quality. - Delayed sleep phase disorder: assists in advancing circadian timing to normalize sleep onset. - Jet lag: supports adaptation to new time zones by synchronizing circadian rhythms.

Adverse reactions reported with melatonin are generally mild and dose‑related.

Common Side Effects: - Drowsiness: feeling of sleepiness during daytime. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness. - Gastrointestinal discomfort: nausea or abdominal cramps.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Mood changes: depression or increased anxiety. - Hormonal effects: alterations in reproductive hormone levels (rare).

When considering melatonin therapy, several safety considerations should be observed.

- Assess underlying conditions: evaluate for depression, seizure disorders, or severe hepatic impairment. - Age considerations: use caution in children and the elderly, adjusting dose as advised. - Concomitant medications: review use of CNS depressants, anticoagulants, or immunosuppressants. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Driving and machinery: do not operate heavy equipment if drowsiness occurs. - Store at room temperature: keep below 25°C in the original container, protect from moisture and light.

Melatonin may interact with other agents that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Anticoagulants: may increase bleeding risk. - Immunosuppressants: could reduce efficacy of melatonin’s immunomodulatory actions.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, alcohol): additive sedative effect. - CYP1A2 inhibitors (fluvoxamine, ciprofloxacin): may raise melatonin plasma levels. - CYP1A2 inducers (rifampicin, smoking): may lower melatonin exposure. - Hormonal contraceptives: may alter melatonin metabolism.